FDA Failures During Heparin Crisis Drive Congress’ Stronger Drug Safety Push
This article was originally published in The Tan Sheet
Executive Summary
FDA's role in the handling of contaminated-heparin crisis is illustrative of "the best and the worst" of its performance under the administration, said David Nelson, senior investigator for the House Energy and Commerce Committee